Abstract
Bipolar Depression (BD) characterised by changes in mood and activity levels is a leading cause of disability worldwide. Current treatments show limited efficacy. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method that is a potential treatment for bipolar depression. We sought to investigate the application of deep learning methods to electroencephalogram (EEG) signals to predict clinical remission. Resting-state EEG data were acquired in 21 BD participants (mean age 51.38 + 10.59 years) at baseline, using a portable 4 electrode EEG device (AF7, AF8, TP9, TP10). Treatment was 6 weeks of home-based tDCS sessions, consisting of 5 sessions per week for 3 weeks and 3 sessions per week for 3 weeks. tDCS was provided in bifrontal montage, anode over left dorsolateral prefrontal cortex (DLPFC) and cathode over right DLPFC, 2 mA, 30 minutes per session. Remission was defined as Montgomery-Åsberg Depression Rating Scale score of less than 8. Power spectral density was derived from EEG signals. Deep learning methods: 1D convolutional neural networks (1DCNNs), long short-term memory (LSTM), gated recurrent units (GRU) and their hybrid models, were investigated for prediction of remission and non-remission status following treatment. Hybrid 1DCNN and GRU model using a combination of delta, theta, and gamma band PSD from AF7 and TP10 electrodes achieved a treatment remission prediction accuracy of 79.55% (sensitivity 76.95%, specificity 83.02%). Compelling prediction accuracy for prediction of treatment remission to a course of tDCS in bipolar depression is achieved from deep learning analysis of resting-state EEG at baseline.
Competing Interest Statement
Authors JM, YF, RW, AG, HR, WX, PR, MB do not report any declarations of interest. CF has received grant funding from: Milken Institute Baszucki Brain Research (BD00000029), National Institute of Mental Health (R01MH134236), Rosetrees Trust (CF20212104), Flow Neuroscience. EB has received grant funding from: MRC (MR/W020238/1), National Institute of Health Research (NIHR200756), NIHR BRC at UCL/UCLH. AY reports the following declaration of interests: Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Novartis, Neurocentrx. Principal Investigator for the following studies: 1. the Restore-Life VNS registry study funded by LivaNova; 2. ESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression; 3. The Effects of Psilocybin on Cognitive Function in Healthy Participants; 4. The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD); 5. A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy. (Janssen); 6. An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD). (Janssen); 7. A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy; 8. A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR. (Janssen). UK Chief Investigator for the following studies: 1. Novartis MDD study MIJ821A12201; 2. Compass; COMP006 & COMP007 studies. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) EU Horizon 2020. Editor of Journal of Psychopharmacology and Deputy Editor, BJPsych Open. No shareholdings in pharmaceutical companies. tDCS devices were provided by Flow Neuroscience.
Clinical Trial
NCT05436613
Funding Statement
CF acknowledges funding support from the Milken Institute Baszucki Brain Research Fund (BD-0000000029) National Institute of Mental Health (R01MH134236) Rosetrees Trust (CF20212104) Flow Neuroscience (FL001). EB acknowledges funding from from MRC (MR/W020238/1) National Institute of Health Research (NIHR200756) and NIHR BRC at UCL/UCLH. Independent research of Professor Young is funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by London - Fulham Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
